At what enterprise value was AMPLITUDE VASCULAR SYSTEMS acquired in 2026?

You can find the full valuation details of AMPLITUDE VASCULAR SYSTEMS on mynth capital. The transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b USD. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of AMPLITUDE VASCULAR SYSTEMS when it was acquired by STRYKER?

The exact EV/EBITDA multiple for AMPLITUDE VASCULAR SYSTEMS is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was AMPLITUDE VASCULAR SYSTEMS acquired by STRYKER?

AMPLITUDE VASCULAR SYSTEMS was acquired by STRYKER in 2026.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the AMPLITUDE VASCULAR SYSTEMS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the AMPLITUDE VASCULAR SYSTEMS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://investors.stryker.com/press-releases/news-details/2026/Stryker-completes-acquisition-of-Amplitude-Vascular-Systems-to-add-next-generation-IVL-technology-to-peripheral-vascular-portfolio/default.aspx

← DATABASE

Home Database Healthcare & PharmaAMPLITUDE VASCULAR SYSTEMS

05/2026

AMPLITUDE VASCULAR SYSTEMS acquired by STRYKER

UNITED STATES Life Sciences / Medical Devices EV 500M - 1.5b USD

Context

Stryker has completed the acquisition of Amplitude Vascular Systems, a private medical device company, which develops a next-generation intravascular lithotripsy (IVL) platform, designed to treat complex peripheral arterial disease, this acquisition represents a significant milestone in the expansion of Stryker's peripheral vascular portfolio, by integrating Amplitude Vascular Systems' innovative technology, which uses carbon dioxide-generated pressure waves, to optimize arterial diameter, while minimizing damage and improving deliverability, treatment speed, and therapeutic efficacy, with the goal of strengthening Stryker's position in peripheral vascular solutions, by offering solutions for physicians and patients, to treat cardiovascular disease, Stryker's strategy is to develop its portfolio of products and services, to improve patient and healthcare outcomes, by offering innovative and integrated solutions, for physicians, hospitals, and patients, financial and legal advisory services were provided by reputable consulting firms, to ensure the success of the operation

AMPLITUDE VASCULAR SYSTEMS, which reported an EBITDA margin of LOGIN in 2026, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Amplitude Vascular Systems is a medical device company based in Boston, Massachusetts, focused on treating severely calcified peripheral arterial disease, offering a next-generation intravascular lithotripsy (IVL) platform designed to treat complex peripheral arterial disease, with a business model based on selling innovative medical devices, such as the Pulse System, which uses carbon dioxide-generated pressure waves to optimize arterial diameter, while minimizing damage and improving deliverability, treatment speed, and therapeutic efficacy, with an experienced management team, including Hitinder Gurm, M.D., interventional cardiologist and chief medical officer, and Robert Chisena, Ph.D., chief technical officer, founded in 2017, with the support of global investors, including BioStar Capital, Cue Growth Partners, and others, to address the needs of patients and physicians in the treatment of cardiovascular disease

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2026

2025

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
06/2026	BRIDGEPOINT	OBAGI MEDICAL	UNITED STATES	Life Sciences	Obagi Medical, a medical-grade skincare company positioned in the professional dermatology and aesthetics segment, is being acquired by Bridgepoint as part of a broader consolidation trend across clinical skincare markets
06/2026	CORDENPHARMA	AMBIOPHARM	UNITED STATES	Life Sciences	CordenPharma, backed by private equity firm Astorg, entered into an agreement to acquire AmbioPharm, a US-based CDMO specializing in complex peptide APIs with manufacturing sites in the United States and China
04/2026	UCB	NEURONA THERAPEUTICS	UNITED STATES	Life Sciences	UCB has entered into a definitive agreement to acquire Neurona Therapeutics, a maneuver designed to fundamentally reinforce the group’s leadership in the global epilepsy market. The strategic rationale for this transaction centers on a "regeneration-acceleration" play, merging the target's industry-leading stem cell platform with the group’s extensive therapeutic expertise and global commercial infrastructure
04/2026	FOR TALENTS / UI INVESTISSEMENT / GENEO	NEFTYS PHARMA	FRANCE	Life Sciences	In a structured minority growth equity transaction, specialized family capital investment firm For Talents has acquired a minority stake in Neftys Pharma. This strategic operation is executed alongside incumbent financial sponsors UI Investissement and GENEO Capital Entrepreneur, who are rolling over their investments after an initial four-year holding period
04/2026	AMERICAN INDUSTRIAL PARTNERS AIP	AVANOS MEDICAL	UNITED STATES	Life Sciences	American Industrial Partners has finalized a definitive agreement to acquire Avanos Medical in an all-cash transaction, a maneuver designed to fundamentally reinforce the target's competitive positioning in the specialized medical technology arena
04/2026	DEVYSER DIAGNOSTICS	CYBERGENE	SWEDEN	Life Sciences	Devyser Diagnostics AB has finalized the acquisition of CyberGene AB from Level Bio AB. The strategic rationale for this transaction centers on a "portfolio-optimization" play, merging the target's established diagnostic kits in aneuploidy and infertility with the group's global commercial infrastructure and direct sales force
04/2026	ASTORG	THERMO FISHER MICROBIOLOGY	UNITED STATES	Life Sciences	Astorg has signed a definitive agreement to acquire Thermo Fisher Scientific's microbiology business, which will become an independent, privately owned platform, backed by Astorg. The transaction consists of a complete corporate carve-out, executed via the Astorg VIII fund, representing the vehicle's tenth investment to date and further concentrating its portfolio exposure within the life sciences sector
04/2026	FINE FOODS & PHARMACEUTICALS	SOFAR	ITALY	Life Sciences	The group has finalized a binding agreement to acquire the total share capital of the target from Alfasigma S.p.A., a maneuver designed to fundamentally expand its specialized manufacturing capabilities
04/2026	REVENIO GROUP CORPORATION	VISIONIX INTERNATIONAL	FRANCE	Life Sciences	The group has finalized a definitive agreement to acquire the entire share capital of the target, a maneuver designed to fundamentally expand its presence as a turnkey provider in the global eye care market
04/2026	VITREX MEDICAL GROUP	HERNIAMESH	ITALY	Life Sciences	Vitrex Medical Group (VMG) has finalized the acquisition of a majority stake in Herniamesh, an operation designed to fundamentally accelerate the group's transformation into a global leader in surgical technology

REFERENCES

Valuation range: EV 500M - 1.5b USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of AMPLITUDE VASCULAR SYSTEMS by STRYKER are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: amplitude vascular systems

Acquirer: stryker